GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

AmCad BioMed 4188.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

14.00

-1.75%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About AmCad BioMed

Its shares trade on Taipei Exchange under the ticker 4188.TWO. It has been listed since 26 December 2013. In the fiscal year to 31 December 2025, it reported revenue of TWD 30.4m and a net loss of TWD 55.7m. At that date it held total assets of TWD 622.7m and shareholders' equity of TWD 521.4m.

AmCad BioMed Corp. engages in the manufacture and sale of medical diagnostic software device. The company is headquartered in Taipei City, Taipei. The company went IPO on 2013-12-26. The Company’s products include AmCAT-UT Dection, which is a computer-aided detection system of thyroid ultrasound, and AmCAD-UT Diagnosis, which is a computer-aided diagnosis system of thyroid ultrasound. The firm operates in Taiwan, China and Hong Kong markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
26 Dec 2013

Leadership

Pay as last reported

  • Ms. Yi-Li LeeChairman of the Board, General Manager, since 2011
  • Ms. Angel LeeVice Chairman of the Board, since 2011
  • Mr. Junlin LiDeputy General Manager-Exhibition Industry
  • Danica DaiHead of Finance & Accounting
  • Ms. Zhiyuan HuangCorporate Governance Officer
  • Mr. Weide ChenDirector
  • Mr. C.C. LeeDirector, since 2011
  • Ms. Shuti QiuDirector
  • Mr. Gary TsengDirector
  • Zaibin WangDirector
  • Mr. Jinchuan XuDirector
  • Mr. Jinjian ZhangDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • AmCad BioMed Corp manufactures AmCAT-UT Detection for thyroid ultrasound in Taiwan market.
  • AmCAD-UT Diagnosis system is a key product for thyroid ultrasound computer-aided diagnosis in Taiwan.
  • The company operates in Taiwan, China, and Hong Kong markets with medical diagnostic software devices.

Weaknesses

  • The company's products are limited to thyroid ultrasound detection and diagnosis systems.
  • AmCad BioMed Corp has no presence in global markets beyond Taiwan, China, and Hong Kong.
  • The company's business is restricted to medical diagnostic software devices only.

Opportunities

  • Expanding into the Chinese market for medical diagnostic software devices could increase revenue.
  • The growing demand for thyroid ultrasound systems in Hong Kong presents an opportunity.
  • AmCad BioMed Corp can leverage its expertise in Taiwan to enter new segments.

Threats

  • Competition from other medical diagnostic software companies in Taiwan is increasing.
  • The company faces regulatory challenges in the Chinese market for medical devices.
  • Hong Kong's market volatility may affect the company's revenue streams.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.